肝移植术后房颤与长期卒中风险
该回顾性队列纳入2010至2018年461例连续成人肝移植患者,术后30天内新发房颤者占10.2%(47例),中位随访4.9年发生21例卒中或系统性栓塞。校正后术后房颤使血栓栓塞风险增加约8倍(HR 8.36,95%CI 2.34-29.79),CHA2DS2VASc评分也是独立预测因素。
要点
- 肝移植术后30天内新发房颤发生率为10.2%,中位发生于术后3天。
- 术后房颤患者血栓栓塞事件率17.0%,显著高于无房颤者的3.1%。
- 术后房颤联合CHA2DS2VASc≥2预测血栓栓塞的C统计量为0.77。
核心结论
- 肝移植术后新发房颤与约8倍的血栓栓塞事件风险独立相关。
- CHA2DS2VASc评分有助于该类患者的风险分层。
- 术后房颤不是长期死亡的独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入2010至2018年连续接受肝移植的成人461例。
- 术后30天内记录到房颤且既往无房颤史者定义为术后房颤(47例,10.2%)。
- 卒中或系统性栓塞由2名独立医师组成的专家组判定。
- 中位随访4.9年(四分位距2.9-7.2年)。
主要发现
- 术后房颤独立预测因素包括高龄、术后脓毒症和左心房扩大。
- 随访期间共发生21例卒中或系统性栓塞事件。
- 术后房颤者血栓栓塞事件率17.0%,无房颤者3.1%(P<0.001)。
- 校正后术后房颤预测血栓栓塞的HR为8.36(95%CI 2.34-29.79)。
- CHA2DS2VASc评分每增加与血栓栓塞风险独立相关(HR 1.58,95%CI 1.02-2.46)。
关键数值与推荐
- 术后房颤定义为肝移植后30天内记录到房颤且既往无房颤史。
- 术后房颤联合CHA2DS2VASc评分≥2预测血栓栓塞的C统计量为0.77,校准良好。
临床怎么用
- 肝移植术后应监测并识别新发房颤,尤其高龄、术后脓毒症或左心房扩大者。
- 对术后房颤患者可结合CHA2DS2VASc评分进行血栓栓塞风险分层。
- 是否启用口服抗凝药降低移植后血栓栓塞风险尚待前瞻性研究验证。
局限性
- 为单中心回顾性队列研究,可能存在残余混杂。
- 血栓栓塞事件数较少(21例),风险估计精度有限。
- 未评估口服抗凝药对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Postoperative atrial fibrillation (POAF) is the commonest cardiovascular complication following liver transplantation (LT). This study sought to assess a possible association of POAF with subsequent thromboembolic events in patients undergoing LT. METHODS: A retrospective cohort study of consecutive adults undergoing LT between 2010 and 2018 was undertaken. Patients were classified as POAF if atrial fibrillation (AF) was documented within 30 days of LT without a prior history of AF. Cases of ischemic stroke or systemic embolism were adjudicated by a panel of 2 independent physicians. RESULTS: Among the 461 patients included, POAF occurred in 47 (10.2%) a median of 3 days following transplantation. Independent predictors of POAF included advancing age, postoperative sepsis and left atrial enlargement. Over a median follow-up of 4.9 (interquartile range, 2.9-7.2) years, 21 cases of stroke and systemic embolism occurred. Rates of thromboembolic events were significantly higher in patients with POAF (17.0% versus 3.1%; P<0.001). After adjustment, POAF remained a strong independent predictor of thromboembolic events (hazard ratio, 8.36 [95% CI, 2.34-29.79]). Increasing CHA2DS2VASc score was also an independent predictor of thromboembolic events (hazard ratio, 1.58 [95% CI, 1.02-2.46]). A model using POAF and a CHA2DS2VASc score ≥2 alone yielded a C statistic of 0.77, with appropriate calibration for the prediction of thromboembolic events. However, POAF was not an independent predictor of long-term mortality. CONCLUSIONS: POAF following LT is associated with an 8-fold increased risk of thromboembolic events and the use of the CHA2DS2VASc score may facilitate risk stratification of these patients. Prospective studies are warranted to assess whether the use of oral anticoagulants can reduce the risk of thromboembolism following LT.
引用
- Koshy AN, Enyati A, Weinberg L, et al. Postoperative Atrial Fibrillation and Long-Term Risk of Stroke in Patients Undergoing Liver Transplantation. Stroke. 2020. PMID: 33349017. doi:10.1161/STROKEAHA.120.031454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。